Filing Analysis
Soligenix, Inc. has filed a prospectus supplement to increase the maximum aggregate offering amount of its common stock under an existing At-Market Issuance Sales Agreement by $2,500,000.
🚩 Red Flags
- Continuous dilution: The company is repeatedly increasing the capacity of its At-the-Market (ATM) offering, indicating a reliance on equity issuance for liquidity.
- Micro-cap financing pattern: Frequent use of ATM offerings is often used by cash-strapped micro-caps to fund operations.
📋 Key Facts
- Increased offering amount: $2,500,000 in additional common stock.
- Existing Sales Agreement date: January 23, 2026, with Rodman & Renshaw LLC.
- Previous sales under the agreement: Approximately $6,234,000.
- Total aggregate amount of shares issuable under the updated agreement: $8,906,000 (calculated from previous $6.4M cap + $2.5M increase).
- The offering is being conducted via an 'At Market' issuance mechanism.
Soligenix received a Nasdaq bid price deficiency notice and simultaneously announced the termination of its HyBryte™ development program following a Phase 3 trial futility recommendation. The company is also transitioning the role of Consulting Chief Medical Officer.
🚩 Red Flags
- Multiple 8-K items in a single filing (3.01, 5.02, 8.01) indicating simultaneous operational and regulatory distress.
- Delisting notice due to low share price, often a precursor to a reverse stock split.
- Termination of a major development program (HyBryte™) due to clinical futility.
- Loss of a key consulting officer (CMO) coinciding with the program termination.
📋 Key Facts
- Received Nasdaq Bid Price Notice on June 10, 2026, for failing to maintain the $1.00 minimum bid price (Rule 5550(a)(2)).
- Deadline to regain compliance is December 7, 2026, or potentially an additional 180 days if a reverse split is planned.
- Board of Directors terminated the HyBryte™ development program on June 11, 2026, after the FLASH2 Phase 3 trial was halted for futility.
- Estimated wind-down costs for the HyBryte™ program are approximately $70,000.
- Dr. Richard C. Straube ceased serving as Consulting Chief Medical Officer on June 11, 2026; responsibilities transitioned to Dr. Christopher Pullion.
- Company is pivoting focus toward dusquetide (SGX945) for Behçet’s Disease and exploring M&A opportunities.
Soligenix, Inc. has increased the maximum aggregate offering amount of common stock issuable under its existing At-The-Market (ATM) issuance sales agreement with Rodman & Renshaw LLC by an additional $2,956,000.
🚩 Red Flags
- Potential for significant shareholder dilution as the company continues to rely on ATM offerings to raise capital.
📋 Key Facts
- The company increased its ATM offering capacity by $2,956,000 on May 28, 2026.
- The company has previously sold approximately $3,445,000 of shares under the same Sales Agreement dated January 23, 2026.
- The offering is conducted through Rodman & Renshaw LLC.
- A legal opinion from Duane Morris LLP was filed as Exhibit 5.1.
Soligenix announced the termination of its Phase 3 FLASH2 trial for HyBryte™ after an interim analysis by the Data Monitoring Committee recommended halting for futility. The company is now exploring strategic alternatives, including potential merger and acquisition opportunities.
🚩 Red Flags
- Phase 3 clinical trial failure (halted for futility), which is a major setback for a micro-cap biotech.
- The company has initiated a search for 'strategic options' and 'merger and acquisition opportunities,' often indicating a lack of viable independent path forward.
- Loss of the primary value driver (HyBryte™) for the company's current pipeline.
📋 Key Facts
- The Phase 3 FLASH2 trial was evaluating HyBryte™ (Synthetic Hypericin) for the treatment of cutaneous T-cell lymphoma.
- The Data Monitoring Committee (DMC) recommended halting the study for futility following an interim efficacy analysis.
- The company is evaluating strategic options including M&A and the potential advancement of dusquetide for Behçet’s Disease.
- The announcement was made via a press release on April 28, 2026.
Soligenix, Inc. issued an 8-K to announce a shareholder update letter from CEO Dr. Christopher J. Schaber. The update covers clinical pipeline developments, upcoming milestones, financing strategies, and the company's cash runway.
🚩 Red Flags
- Mention of 'financing strategies' and 'cash runway' often implies a need for capital or potential liquidity concerns, though specific figures are not provided in this summary filing.
📋 Key Facts
- Filed on February 12, 2026.
- CEO Dr. Christopher J. Schaber issued a shareholder update letter via press release (Exhibit 99.1).
- The update includes details on clinical developments and upcoming milestones.
- The company addressed financing strategies and cash runway in the communication.
Soligenix, Inc. entered into an At-the-Market (ATM) issuance sales agreement with Rodman & Renshaw, LLC to facilitate the sale of up to $3.45 million in common stock.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can signal liquidity needs.
📋 Key Facts
- Entered into an At Market Issuance Sales Agreement with Rodman & Renshaw, LLC on January 23, 2026.
- Aggregate offering price: up to $3,450,000.
- Commission rate: up to 3.0% of gross proceeds.
- Agreement expires on the earliest of December 15, 2026, or upon full sale/termination.
- Shares will be issued under an existing Form S-3 shelf registration statement (File No. 333-274265).
Soligenix, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement. The company previously received a notice of non-compliance on August 15, 2025, but current filings confirm the matter is now closed.
🚩 Red Flags
- Historical non-compliance with Nasdaq minimum stockholders' equity requirements (previously disclosed).
📋 Key Facts
- Nasdaq required a minimum stockholders' equity of $2,500,000 per Listing Rule 5550(b)(1).
- As of the September 30, 2025, quarterly report, the Company reported stockholders' equity of $7,597,976.
- Nasdaq confirmed on November 18, 2025, that the company has regained compliance and the matter is closed.
Soligenix, Inc. closed a $7.5 million public offering of common stock and warrants on September 29, 2025. The proceeds are intended to extend the company's cash runway through the end of 2026 to fund R&D and commercialization activities.
🚩 Red Flags
- Significant dilution: The issuance of over 5.5 million common warrants and 1.4 million pre-funded warrants represents substantial potential future dilution for existing shareholders.
- Restrictive covenants: The company is prohibited from issuing new securities (except ATM offerings) for 60 days and cannot enter variable rate transactions for one year.
📋 Key Facts
- Total gross proceeds from the offering: approximately $7.5 million.
- Securities issued include 4,064,080 shares of common stock, 1,491,480 pre-funded warrants, and 5,555,560 common warrants.
- Unit price for common stock/warrant units: $1.35 per unit.
- Common warrants are exercisable at $1.35 per share with a five-year term.
- The offering extends the company's cash runway through the end of 2026.
- Placement agent A.G.P./Alliance Global Partners received a 6.5% cash fee plus $90,000 in expenses.
Soligenix, Inc. announced that the FDA's Office of Orphan Products Development has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet’s Disease. This follows Phase 2a clinical results indicating biological efficacy and safety.
📋 Key Facts
- FDA granted orphan drug designation to dusquetide (active ingredient in SGX945).
- Target indication: Treatment of Behçet’s Disease.
- Designation follows review of Phase 2a clinical results demonstrating efficacy and safety.
Soligenix, Inc. received a notice from Nasdaq stating it is in non-compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company reported $1,828,951 in stockholders' equity as of June 30, 2025, falling short of the required $2,500,000.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum stockholders' equity)
- Failure to meet alternative listing standards (market value and net income)
- Significant capital shortfall relative to exchange requirements
- Potential for delisting if compliance plan is not accepted or executed within 180 days
📋 Key Facts
- Nasdaq notice received on August 15, 2025.
- Stockholders' equity reported in Q2 (ended June 30, 2025) was $1,828,951.
- Minimum stockholders' equity requirement for Nasdaq is $2,500,000.
- The company generated approximately $1,439,300 in gross proceeds via an ATM facility on July 1, 2025 (not yet reflected in the June 30 report).
- Company fails alternative listing standards: market value of listed securities ($35M) and net income ($500k).
- The company has until September 29, 2025, to submit a plan to regain compliance.
Soligenix, Inc. announced the successful completion of its Phase 2a proof-of-concept study for SGX945 (dusquetide) in treating Behçet's Disease. The study met its primary objective by demonstrating biological efficacy.
📋 Key Facts
- Completed Phase 2a proof of concept study for SGX945 (dusquetide).
- Target indication: Behçet's Disease.
- Study achieved the objective of demonstrating biological efficacy.
Soligenix, Inc. held its 2025 annual meeting of stockholders on June 20, 2025. Shareholders approved the 2025 Equity Incentive Plan, elected five directors, ratified the appointment of Cherry Bekaert, LLP as auditors, and approved executive compensation via non-binding advisory vote.
🚩 Red Flags
- Approval of an adjournment proposal suggests the company may have faced difficulty reaching a quorum or sufficient votes during the initial meeting phase.
📋 Key Facts
- Annual Meeting held on June 20, 2025.
- Stockholders approved the '2025 Equity Incentive Plan' (Proposal 2).
- Five directors were elected: Christopher J. Schaber, PhD; Gregg A. Lapointe, CPA, MBA; Diane L. Parks, MBA; Robert J. Rubin, MD; and Jerome B. Zeldis, MD, PhD.
- Cherry Bekaert, LLP was ratified as the independent registered public accounting firm for fiscal year 2025 (Proposal 4).
- Non-binding advisory vote on executive compensation was approved (Proposal 3).
- Adjournment proposal was approved to allow for further proxy solicitation if needed (Proposal 5).
Soligenix, Inc. has amended its bylaws to significantly reduce the quorum requirement for stockholder meetings from a majority of voting power to one-third (1/3). This change is intended to prevent meeting failures caused by a dispersed shareholder base and recent brokerage policy changes regarding discretionary voting.
🚩 Red Flags
- Governance Risk: Reducing quorum requirements can make it easier for minority shareholders (or those with concentrated holdings) to pass resolutions without broad consensus.
- Operational Friction: The company explicitly admits to 'challenges in achieving quorum at prior stockholder meetings,' indicating historical governance instability.
📋 Key Facts
- Effective Date: March 25, 2025
- Quorum Change: Reduced from a majority of outstanding voting power to one-third (1/3) of voting power present in person or by proxy.
- Reasoning provided: Difficulty achieving quorum due to dispersed shareholder base and changes in brokerage firm policies curtailing discretionary voting authority.
Soligenix, Inc. has fully repaid and terminated its Loan and Security Agreement with Pontifax Medison Finance entities. The termination includes the release of all related liens and security interests without incurring prepayment penalties.
🚩 Red Flags
- None identified in this specific filing; however, full repayment of debt often implies significant cash outflow or restructuring which should be verified against upcoming cash flow statements.
📋 Key Facts
- Repaid in full all outstanding obligations under the Loan and Security Agreement dated December 15, 2020.
- Lenders include Pontifax Medison Finance (Israel) L.P., Pontifax Medison Finance (Cayman) L.P., and Pontifax Medison Finance GP, L.P.
- All related liens and security interests securing the obligations have been terminated and released.
- The Company did not incur any prepayment penalties for the early repayment.
- The loan was originally a $10 million facility issued over four years ago.
Soligenix, Inc. has amended its existing Loan and Security Agreement to allow for the satisfaction of remaining debt through the issuance of common stock rather than cash. This move is intended to preserve cash runway by converting debt into equity at specific conversion prices.
🚩 Red Flags
- Debt-for-equity swap: Indicates significant liquidity constraints and a need to preserve cash by diluting existing shareholders.
- Potential massive dilution: The conversion of debt into equity directly increases the share count, which typically puts downward pressure on stock price.
📋 Key Facts
- Amendment dated October 8, 2024, with Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.
- The amendment allows remaining loan amounts to be satisfied with stock in lieu of cash.
- Conversion price for the first 501,648 shares is set at $3.81.
- Conversion price for any shares exceeding 501,648 is set at $4.23.
Soligenix, Inc. entered into an At-the-Market (ATM) sales agreement with A.G.P./Alliance Global Partners to facilitate the sale of up to $5.8 million in common stock. This allows the company to raise capital incrementally at prevailing market prices through its existing shelf registration.
🚩 Red Flags
- Potential for significant shareholder dilution through continuous issuance of common stock.
📋 Key Facts
- Entered into an At Market Issuance Sales Agreement with AGP on August 16, 2024.
- Aggregate offering price of up to $5.8 million in common stock.
- AGP will receive a fixed commission rate of up to 3.0% of gross proceeds.
- The agreement is valid until December 15, 2026, or until the maximum amount is raised/terminated.
- Shares are being issued under an existing S-3 shelf registration statement (File No. 333-274265).
Soligenix, Inc. has received confirmation from Nasdaq that it has regained compliance with the Minimum Bid Price Rule (Nasdaq Listing Rule 5450(a)(1)). This follows a 1-for-16 reverse stock split executed in June 2024 to address previous non-compliance.
🚩 Red Flags
- History of non-compliance with Nasdaq minimum bid price requirements.
- Execution of a 1-for-16 reverse stock split (typically viewed as a sign of distress in micro-caps).
📋 Key Facts
- Received Nasdaq confirmation on July 24, 2024, regarding compliance with the Minimum Bid Price Rule.
- The Company previously failed to maintain a minimum closing bid price of $1.00 for 30 consecutive trading days.
- A 1-for-16 reverse stock split was implemented on June 5, 2024, to boost share price.
- Nasdaq Hearings Panel has closed the delisting matter following the successful compliance.
Soligenix, Inc. entered into a warrant inducement agreement to encourage existing warrant holders to exercise their warrants for cash. In exchange, the company is issuing new warrants with a significant 150% coverage ratio, leading to substantial potential dilution.
🚩 Red Flags
- Significant Dilution: The 150% coverage ratio on new warrants represents massive potential dilution for existing shareholders.
- Liquidity Pressure: The use of 'warrant inducement' often indicates the company is struggling to raise capital through traditional means and must offer highly favorable terms to secure immediate cash.
- Unregistered Securities: The new warrants are unregistered, requiring a mandatory S-1 filing by July 25, 2024.
📋 Key Facts
- Date of Agreement: July 9, 2024
- Existing Warrants: Up to 703,125 shares at $6.00 per share.
- Potential Gross Proceeds: Approximately $4,218,750 if all warrants are exercised.
- New Warrants: Issued at a 150% coverage ratio (for every 1 share exercised, 1.5 new warrant shares are issued).
- New Warrant Terms: Immediately exercisable with a five-year term and an exercise price of $6.00 per share.
- Registration Obligation: Company must file an S-1 registration statement for the resale of New Warrant Shares by July 25, 2024.
- Advisory Fees: A.G.P./Alliance Global Partners to receive a 6.0% fee of aggregate gross proceeds plus up to $40,000 in legal expense reimbursement.
Soligenix, Inc. has announced a 1-for-16 reverse stock split effective June 5, 2024, following stockholder approval at the company's Annual Meeting. The move will reduce outstanding shares from approximately 15.8 million to roughly 987,490.
🚩 Red Flags
- Reverse stock split (often used to combat delisting or improve share price perception)
- Significant reduction in the number of outstanding shares
📋 Key Facts
- Reverse stock split ratio: 1-for-16
- Effective date of split: June 5, 2024, at 4:00 p.m. EST
- New trading basis on Nasdaq Capital Market: June 6, 2024
- Shares outstanding reduction: From ~15,799,837 to ~987,490 shares
- Stockholder approval obtained for the split via a range of 1-for-2 to 1-for-20
- The company's ticker symbol 'SNGX' remains unchanged.
Soligenix, Inc. failed to reach a quorum at its 2024 Annual Meeting of Stockholders held on May 23, 2024. Consequently, the meeting was adjourned without conducting any business and is scheduled to reconvene on May 30, 2024.
🚩 Red Flags
- Failure to reach a quorum indicates low shareholder engagement or potential issues with proxy solicitation/shareholder participation.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders convened on May 23, 2024.
- A quorum was not present or represented by proxy at the meeting.
- The Annual Meeting has been adjourned without transacting any business.
- The reconvened meeting is scheduled for May 30, 2024, via live audio-only webcast.
Soligenix, Inc. reports that it is currently in compliance with the Nasdaq requirement to maintain a minimum shareholders' equity of at least $2,500,000. This compliance follows a debt-to-equity conversion and a successful public offering completed in April 2024.
🚩 Red Flags
- Historical liquidity/equity issues: The filing implies a recent risk of non-compliance with Nasdaq equity requirements, which is common for distressed micro-cap biotech firms.
📋 Key Facts
- Company maintains compliance with Nasdaq's $2.5 million minimum shareholders' equity requirement as of May 17, 2024.
- Compliance achieved via two primary events: (i) conversion of $154,840 of debt into equity on April 15, 2024, and (ii) a $4.75 million public offering closed on April 22, 2024.
- The financing activities were previously disclosed in the 10-Q filed on May 10, 2024.
Soligenix, Inc. completed a public offering of common stock and warrants on April 22, 2024, raising approximately $4.75 million in gross proceeds. The offering includes significant warrant coverage that will lead to substantial future dilution.
🚩 Red Flags
- Significant potential dilution: The number of warrants (20.475M total) far exceeds the common shares issued in this round.
- Low share price: Offering conducted at $0.40 per unit, indicating a highly distressed or micro-cap valuation.
- Restrictive covenants: 90-day ban on issuing new securities and a 1-year ban on variable rate transactions (except ATM).
📋 Key Facts
- Offering closed on April 22, 2024.
- Total gross proceeds: approximately $4.75 million before fees.
- Securities issued: 3,275,000 shares of common stock, 8,600,000 pre-funded warrants, and 11,875,000 common warrants.
- Unit price: $0.40 per unit (common stock + warrant) or $0.399 per unit (pre-funded warrant + warrant).
- Common warrants are exercisable at $0.40 per share with a five-year term.
- Placement agent A.G.P./Alliance Global Partners received a 6.5% cash fee plus $90,000 in expenses.
Soligenix, Inc. announced that the European Medicines Agency (EMA) has agreed on the design components for a confirmatory Phase 3 study of HyBryte™ for treating cutaneous T-cell lymphoma. The company expects to begin patient enrollment by late 2024.
📋 Key Facts
- EMA agreement reached on key design components for a confirmatory Phase 3 placebo-controlled study for HyBryte™ (synthetic hypericin).
- The study targets cutaneous T-cell lymphoma patients with early-stage disease.
- Enrollment is expected to include approximately 80 patients across the US and Europe.
- Patient enrollment is targeted to begin by the end of 2024.
- Top-line results from the Phase 3 study are anticipated in the second half of 2026.